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Summary
Lymphocytes in T cell activation require extracellular
nutrients to provide energy for cellular proliferation
and effector functions. Therefore, inhibitors of nutri-
ent transporters are expected to be a new class of im-
munosuppressant. Here, we report that the molecular
target of brasilicardin A (BraA), an immunosuppres-
sive compound, is the amino acid transporter system
L. BraA inhibited the cell-cycle progression of murine
T cell lymphocyte CTLL-2 cells in G1 phase, and po-
tently inhibited the uptake of amino acids that are sub-
strates for amino acid transport system L. Moreover,
BraA stimulated the GCN2 activation and, subse-
quently, the phosphorylation of eIF2a. These results
suggest that the immunosuppressive activity of BraA
is induced by amino acid deprivation via the inhibition
of system L and that the amino acid transporter is a
target for immunosuppressant.
Introduction
The use of cyclosporin and FK-506 has improved graft
survival rates in cases of organ transplantation. It is
well known that the immunosuppressive effects of
both drugs depend on the inhibition of calcineurin [1].
However, these beneficial effects of immunosuppres-
sion have remained limited, because both drugs can in-
duce nephrotoxicity and arterial hypertension [2, 3].
These side effects are also dependent on the inhibition
of calcineurin. Rapamycin, another immunosuppressive
drug, targets a different stage of the immune response
from that of cyclosporin and FK-506 [4]. Studies of its
mechanism of action have led to the discovery of the
mTOR pathway, an evolutionarily conserved signaling
network that plays critical roles in eukaryotic cell growth
and cell-cycle progression [5]. mTOR participates in nu-
trient-sensitive signaling, and rapamycin mimics a signal
generated by amino acid starvation. Interestingly, lym-
phocytes are more dependent than other cell types on
amino acids. Glutamine is required for biosynthesis
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quate concentration of glutamine compromises lym-
phocyte proliferation [6, 7]. Cells of the innate immune
system can also control the T cell response by regulat-
ing the extracellular concentration of tryptophan [8, 9].
Recently, the monocarboxylate transporter, MCT1, was
identified as the target molecule of another type of im-
munosuppressive compound, the pyrrolo[3,4-d]pyrimi-
dine-2,4-diones derivatives [10, 11]. Studies of these
compounds have shown that they inhibited increases
in the rate of glycolysis, which is required for the rapid
phase of cell division in T cell activation, via an inhibition
of lactate efflux. These results strongly suggest that high
energy levels and nutrients are required for T cell activa-
tion [12], and inhibitors of nutrient transporters might be
a novel type of immunomodulator.
Organic nutrients, such as sugars and amino acids,
are provided to cells via transporters situated on the
plasma membrane. Amino acid transporters are classi-
fied based on their substrate selectivity and Na+ depen-
dency [13]. The transport of large neutral amino acids
with branched or aromatic side chains is mediated by
Na+-independent amino acid transport system L [13,
14]. At the molecular level, system L is identical to 4F2
antigen (CD98), which consists of two subunits, 4F2hc/
SLC3A2, a type II membrane protein (heavy chain), and
a membrane protein LAT1/2 (L-type amino acid trans-
porter 1 or 2; light chain). The 4F2 antigen was originally
identified as a cell-surface antigen associated with lym-
phocyte activation [15, 16]. The 4F2 antigen is involved
in a variety of cellular activities, such as cell activation,
growth, and adhesion [15–18]. To function as an amino
acid transporter, 4F2hc is necessary for the trafficking
of the light chain to the plasma membrane, whereas
the light chains are thought to determine the transport
characteristics. LAT1 requires a free carboxyl and an
amino group for an aromatic amino acid to be used as
a substrate, and the hydrophobic interaction between
the substrate side chain and the substrate binding
site of LAT1 appears to be crucial for substrate binding
[19].
Brasilicardin A (BraA; Figure 1), a natural product iso-
lated from the cultured broth of Nocardia brasiliensis
IFM0406, consists of an amino acid moiety and an
anti/syn/anti-perhydrophenanthrene skeleton with a
sugar moiety (a rhamnose, an N-acetylglucosamine
[GlcNAc], and 3-hydroxybenzoate) [20, 21]. This com-
pound has been shown to exhibit immunosuppressive
activity in a mouse mixed-lymphocyte reaction assay
system, with an IC50 of 0.057 mg/ml, but it did not exert
any inhibitory activity against interleukin (IL) 2 produc-
tion, suggesting that the inhibition point of BraA might
differ from that of other immunosuppressive drugs,
such as cyclosporin, FK-506, and rapamycin. Here, we
report that BraA arrested cell-cycle progression at G1
phase without inhibiting the IL-2 signaling involving
Jak3/STAT5, the Ras-MAK kinase cascade, and the
phosphatidylinositol 3-kinase (PI3K) pathway. The pres-
ent structure-activity relationship (SAR) analysis sug-
gests that BraA disturbs amino acid metabolism.
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inhibitor of amino acid transporter system L. These re-
sults suggest that amino acid transport system L is,
therefore, a novel target for immunosuppressants.
Results
BraA Inhibits Cell-Cycle Progression at G1 Phase
without Interfering with IL-2 Signaling
BraA (Figure 1A) was isolated as a potent immunosup-
pressive compound; however, the mechanism of sup-
pression remained unclear. To reveal this inhibition
mechanism, we examined the effects of the compound
on the cell-cycle progression of CTLL-2 cells, a cytotoxic
T cell line dependent on IL-2 for growth. CTLL-2 cells
were treated with DMSO, rapamycin, or BraA for 18 hr.
Rapamycin showed some accumulation in G1 cells
(Figure 1B). On the other hand, BraA inhibited cell-cycle
progression at G1 phase in a dose-dependent manner.
Next, we examined whether or not BraA arrests cell-
cycle progression at G1 phase by inhibiting IL-2 signal-
ing. The propagation of IL-2-mediated signal transduc-
tion occurs following the binding of the ligand to
a high-affinity IL-2 receptor complex, and at least three
distinct pathways are activated: JAK-STATs, the Ras-
MAP kinase cascade, and the PI3K pathway [22–24].
These signaling proteins regulate gene transcription
controlling cell growth, differentiation, and immune re-
sponsiveness. To test the effects of BraA on IL-2 signal-
ing, we employed an IL-2 deprivation and restimulation
Figure 1. Structure and Effects of BraA on Cell-Cycle Progression
(A) Structure of BraA.
(B) Effects of various drugs on the cell-cycle progression of CTLL-2
cells. Asynchronous CTLL-2 cells were treated with Rap (100 nM)
and BraA (30 and 100 nM) for 18 hr.assay of CTLL-2 cells. Six hours of IL-2 deprivation re-
sulted in the inactivation of most signaling pathways,
based on the phosphorylation levels of STAT5 (Fig-
ure 2A), ERK1/2, mTOR, p70S6k, and S6 protein
(Figure 2B). Jak3 kinase was activated and phosphory-
lated the Tyr694 of STAT5, a substrate of Jak3, 30 min
after the addition of IL-2 (Figure 2A). This phosphoryla-
tion was completely abolished by pretreatment with
200 nM Jak inhibitor I [25]. However, the STAT5 phos-
phorylation levels in the presence of rapamycin (100
nM) or with a high concentration of BraA (3 mM) were
similar to those of the DMSO-treated cells, indicating
that BraA interferes neither with IL-2 binding to its re-
ceptor nor with the subsequent Jak3 kinase activation
(Figure 2A). Next, we investigated the effects of BraA
on both the Ras-MAP kinase cascade and the PI3K
pathway (Figure 2B). Activation of the Ras-MAP kinase
cascade and the PI3K pathway was detected by the
phosphorylation of ERK1/2 and mTOR, respectively.
The phosphorylation of p70S6k and its substrate, S6
ribosomal protein, was also investigated, because
p70S6k is a meeting point of the Ras-MAP kinase cas-
cade and the PI3K pathway, and p70S6k regulates the ef-
ficiency of protein synthesis via the phosphorylation of
S6 ribosomal protein. Both ERK1/2 and mTOR were
phosphorylated by IL-2 stimulation, irrespective of the
presence of rapamycin. However, the phosphorylation
of p70S6k and S6 was completely blocked by rapamycin,
thus indicating that 100 nM rapamycin inhibited the ki-
nase activity, but not the activation of mTOR. On the
other hand, there was either no change, or only a slight
decrease in the phosphorylation levels of ERK1/2,
mTOR, p70S6k, and S6 by treatment with 100 nM BraA.
These results suggest that BraA inhibits cell-cycle
progression at G1 phase without interfering with IL-2
signaling.
Amino Acid Moiety of BraA Is Important for G1
Arrest of CTLL-2 Cells
To help identify the molecular target of BraA, we next
investigated the relationship between cell-cycle arrest
activities and BraA structure. The structures and the
effects of BraA natural derivatives BraC (2) and semi-
synthetic analogs (3–7) on the cell-cycle progression
of CTLL-2 cells are shown in Figures 3A and 3B, res-
pectively. All compounds reduced G1 arrest activity,
as compared with the results obtained with BraA (Fig-
ure 3B; compound 1, 300 and 100 nM). BraC, a BraA de-
rivative lacking both an N-acetylglucosamine (GlcNAc)
and a 3-hydroxybenzoate, also accumulated in the G1
cells at a dose of 10 mM, suggesting that a GlcNAc
and/or a 3-hydroxybenzoate are important, though not
necessary, for cell-cycle inhibition. Compound 3 in-
hibited cell-cycle progression at G1 phase at concentra-
tions above 1 mM, but did not at 300 nM (Figure 3B, data
not shown). However, since compound 3 is a methyl-
ester derivative, there remained the possibility that com-
pound 3 was converted to the original compound 1 by
cellular esterase, and then exhibited cell-cycle arrest
activity. In contrast, all other derivatives containing
a modified amino acid moiety (4–6) showed no cell-cycle
inhibitory activity. Thus, these results suggest that the
amino acid moiety of BraA is important for the inhibition
of cell-cycle progression.
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CTLL-2 cells were deprived of IL-2 for 6 hr,
and the cells were incubated with various
drugs for the final 30 min. IL-2 was added af-
ter a 6 hr deprivation period, and incubation
was continued for an additional 30 min.
(A) Effects of BraA on the phosphorylation of
STAT5 induced by IL-2. IL-2-deprived CTLL-
2 cells were treated with Jak kinase inhibitor
(Jak inh., 200 nM), BraA (3 mM), and Rap
(100 nM) for 30 min.
(B) Effects of BraA on Ras-MAP kinase and
PI3K pathways. IL-2-deprived CTLL-2 cells
were treated with BraA (100 nM) and rapa-
mycin (Rap, 100 nM) for 30 min.BraA Is a Novel Inhibitor of Amino Acid Transport
It is well known that lymphocytes are sensitive to amino
acid starvation. Cells of the innate immune system can
also control the T cell response by regulating the extra-
cellular concentration of tryptophan by indoleamine 2,3-
dioxygenase. Since the SAR analysis suggested that the
amino acid moiety of BraA is important for cell-cycle in-
hibition, we suspected that BraA disturbs amino acid
metabolism in the cells. Because cycloheximide, a po-
tent protein synthesis inhibitor, strongly inhibited the
cell-cycle progression of CTLL-2 cells at G1 phase
(data not shown), it was considered possible that BraA
is a protein synthesis inhibitor. However, BraA did not
exhibit any inhibitory activity against in vitro protein syn-
thesis when reticulocyte lysate was used (data not
shown). We therefore speculated that BraA targets the
molecule(s) involved in amino acid metabolism up-
stream of protein synthesis. One of the most attractive
explanations for the results is that BraA targets the sys-
tem for the transport of amino acid(s) required for T cell
proliferation. Thus, we subsequently investigated the
uptake of several amino acids using HeLa cells and
found that 100 nM BraA strongly inhibited the uptake
of amino acids containing a large neutral side chain
(Ile, Leu, Met, Phe, Trp, and Val), but not that of amino
acids containing acidic (Glu), basic (Lys), or small side
chains (Gly, Pro, Ser) (Figure 4A). This inhibitory spec-
trum is identical to the substrate specificity of amino
acid transport system L. System L transports several
amino acids containing a large neutral side chain in
a Na+-independent manner, and this system is sensitive
to 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid(BCH), a system L-specific inhibitor. As expected, the in-
hibitory spectrum of BCH (2 mM) was completely identi-
cal to that of BraA, which strongly suggested that BraA
targets system L. The mode of inhibition of BraA on the
uptake of Met was competitive with the Ki of 12.2 nM
(Figure 4B). The IC50 values of BraA derivatives listed
in Table 1 showed a good correlation with the concen-
trations required for cell-cycle inhibition, with the excep-
tion of those for compound 3. Thus, the present results
suggest that system L inhibition by BraA induces G1
arrest.
BraA Induces Integrated Stress Responses In Situ
There are two signaling pathways to protect cells
against amino acid starvation: one is the nutrient-sensi-
tive mTOR pathway, and the other is the GCN2 pathway.
Thus, we next examined the effects of BraA on the activ-
ity of both of these pathways. IL-2-stimulated CTLL-2
cells were cultured in the presence of 100 nM BraA or ra-
pamycin for 18 hr, and the phosphorylation of the sub-
strates of mTOR (p70S6k on Ser389) and GCN2 (eIF2a
on Ser51) was investigated. As shown in Figure 5A,
phosphorylation on Ser389 of p70S6k was completely in-
hibited by rapamycin. BraA treatment also reduced the
phosphorylation of p70S6k, but this decrease was not
as marked as that obtained with rapamycin treatment,
suggesting that the G1 arrest activity of BraA (Figure 1B)
is not dependent on the downregulation of the mTOR
pathway. On the other hand, the phosphorylation on
Ser51 of eIF2a was stimulated by BraA treatment. It
has already been established that there are at least
four eIF2a kinases that are activated by distinct
Chemistry & Biology
1156Figure 3. Structure and Effects of BraA De-
rivatives on Cell-Cycle Progression
(A) Structure of BraA derivatives.
(B) Effects of BraA (1) and its derivatives on
the cell-cycle progression of CTLL-2 cells.
Asynchronous CTLL-2 cells were treated
with BraA derivatives for 18 hr.upstream stress signals [26]. To confirm GCN2 activa-
tion by BraA treatment, we assessed the phosphoryla-
tion on The898 of GCN2, which is among the autophos-
phorylation sites located in the activation loop. It was
revealed that GCN2 phosphorylation also occurred
with 18 hr of BraA treatment (Figure 5A). Activation of
GCN2 and subsequent eIF2a phosphorylation were in-
duced within 1 hr after the addition of BraA (Figure 5B).
Finally, we examined the effects of amino acid depriva-
tion on cell-cycle progression. CTLL-2 was cultured in
medium lacking the amino acids that are substrates
for system L (His, Ile, Leu, Met, Phe, Trp, Tyr, and Val)
for 18 hr. As shown in Figure 5C, amino acid deprivation
induced cell-cycle arrest at G1 phase, as was also the
case with BraA treatment in the presence of amino acids
(Figure 1B). These results strongly suggest that BraA
evokes integrated stress responses via decreases in
the intracellular amino acid pool, and thus inhibits cell-
cycle progression at G1 phase.
Discussion
BraA Is a Potent Inhibitor of Amino Acid Transport
System L
In the current study, we investigated the effects and
molecular target of an immunosuppressive compound,BraA, and demonstrated that BraA is a potent inhibitor
of amino acid transport system L. System L transports
large neutral amino acids in an Na+-independent manner
and is sensitive to a system L-specific inhibitor, BCH [13,
14]. There are two types of system L: (1) a heterodimeric
transporter composed of 4F2 antigen (CD98; heavy
chain) and LAT1/2 (light chain); and (2) a monomeric
transporter, LAT3/4. A heterodimeric transporter was
originally identified as a cell-surface antigen associated
with lymphocyte activation [15, 16], suggesting that an
extraordinary uptake of amino acids is required for
T cell activation.
We revealed that BraA strongly inhibits the uptake of
Ile, Leu, Met, Phe, Trp, and Val, but not that of Glu,
Lys, Gly, Pro, or Ser (Figure 4A). The inhibitory spectrum
of BraA was completely identical to that of BCH and re-
flected the substrate specificity of amino acid transport
system L. Furthermore, the IC50 values of BraA and BCH
were 14.5 nM and 52.8 mM, respectively, indicating that
BraA is approximately 3000-fold more potent an inhibi-
tor than BCH (Table 1). These results clearly indicate
that BraA is a novel and potent inhibitor of system L.
Based on the SAR of BraA, it was revealed that: (1)
the sugar moiety is important, but not necessary; and
(2) a free amino group is necessary for the inhibition
of both cell-cycle progression and system L (Figure 3
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ural BraA derivative lacking both a GlcNAc and a 3-hy-
droxybenzoate, showed only 2-fold weaker inhibitory
activity with respect to system L than did BraA, but
its activity was approximately 30-fold weaker in terms
of cell-cycle inhibition. Furthermore, BCH could not in-
hibit the cell-cycle progression even at 2 mM. Although
it is difficult to estimate the concentration of amino
acids required for cell-cycle progression, we assume
that complete inhibition of amino acid transport is re-
quired for cell-cycle arrest. The amino acids required
to promote the cell cycle might be supplied by the deg-
Figure 4. Effects of BraA on the Uptake of Amino Acids
(A) The uptake of tritium-labeled amino acids into HeLa cells was
tested in the presence of 100 nM BraA (open bars) or 2 mM BCH
(closed bars). Bars represent mean + SD obtained from three inde-
pendent experiments.
(B) Double reciprocal plot analyses of the inhibitory effects of BraA
on [3H]methionine uptake. The uptake of [3H]methionine (250, 333,
500, and 1000 mM) was measured in the presence of BraA (closed
squares, 20 nM; closed triangles, 40 nM; closed circles, 60 nM)
as well as without BraA (open circles).
Table 1. IC50 Values of BraA Derivatives on Met Uptake
Compound IC50 (nM)
1 (BraA) 14.5 6 1.3
2 (BraC) 25.3 6 5.0
3 3,500 6 100
4 1,700 6 100
5 6,200 6 300
6 1,800 6 100
BCH 52,800 6 400
HeLa cells were preincubated for 5 min in the presence of the drugs,
after which the medium was replaced by uptake solution containing
tritium-labeled methionine; the cells were then incubated for an ad-
ditional 15 min. Means6 standard deviation obtained from three in-
dependent experiments are shown.radation of cellular proteins, a stress response trig-
gered by amino acid deprivation. It also appears to
be noteworthy that compound 3, a methylester deriva-
tive of BraA at the carboxylate moiety, showed cell-cy-
cle inhibition, but not system L inhibition (Figure 3B
and Table 1). It is possible that compound 3 converted
to active compound 1 by cellular esterase, as seen in
our previous SAR analysis of reveromycin analogs
[27]. The 10 min incubation in our system L assay might
not have been sufficient to convert compound 3 to
compound 1; therefore, no inhibition was observed in
the amino acid transport assay. The other derivatives
modified by an amino acid moiety (4–6) showed no
cell-cycle inhibitory activity, and only weak inhibition
was observed against system L (Figure 3B and Table
1). These results suggest that at least a free amino
group is necessary for the inhibition of both cell-cycle
progression and system L by BraA. The requirement
of a free amino group is coincident with the structural
features of system L substrates [19]. Taken together
with the kinetic data showing that BraA competitively
inhibits Met uptake (Figure 4B), these results strongly
suggest that the amino acid moiety of BraA binds on
the substrate binding site of system L.
BraA Induces Integrated Stress Responses
in CTLL-2 Cells
It should be noted that BraA exerted only a slight influ-
ence on IL-2 signaling involved in the Jak3-STAT5,
Ras-MAP kinase, and PI3K pathways, and BraA strongly
inhibited the cell-cycle progression at G1 phase (Figures
1 and 2). The question remains regarding how the inhibi-
tion of amino acid transport by BraA results in cell-cycle
arrest at G1 phase. It is assumed that the BraA-treated
cells were unable to take up large, neutral amino acids,
and that they would undergo amino acid deprivation
as a result. It is known that such amino acid-starved
conditions lead to the accumulation of uncharged
tRNA and then evoke the GCN2 kinase-mediated inte-
grated stress response [28]. GCN2 is the primary sensor
of amino acid starvation, and activated GCN2 kinase
phosphorylates the eIF2a on Ser51 (Figures 5A and
5B). The phosphorylation of eIF2a converts eIF2 from
a substrate to an inhibitor of guanine nucleotide ex-
change factor eIF2B by stabilizing the eIF2a-GDP-
eIF2B interaction. Since eIF2 is present at higher levels
than eIF2B, the phosphorylation of only a fraction of
eIF2 can lead to significant eIF2B sequestration and a re-
sultant dramatic inhibition of translation. Therefore, we
assume that BraA treatment evokes the blockage of pro-
tein translation in situ. Although we noted previously
here that BraA had no effect on in vitro protein synthesis
(data not shown), it is thought that externally supplied
amino acids suppressed the integrated stress response
system in vitro. Furthermore, not only a reduction in pro-
tein synthesis, but also eIF2a phosphorylation plays
a pivotal role in cell-cycle arrest at G1 in the case of clor-
imazole-induced Ca2+ deprivation [29] and of tunicamy-
cin-induced ER stress [30, 31]. Recent evidence has in-
dicated that ER stress-induced G1 arrest resulted from
the specific loss of cyclin D1 protein via an inhibition of
the translation of cyclin D1 [32]. The results of previous
reports, when taken together with our findings, strongly
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Induce Integrated Stress Responses
(A) Effects of BraA on the phosphorylation of
eIF2a, p70S6k, and GCN2. CTLL-2 cells culti-
vated in the presence of IL-2 were treated
with BraA (100 nM) and rapamycin (Rap,
100 nM) for 18 hr.
(B) The phosphorylation of GCN2 and eIF2a
was rapidly induced by BraA treatment.
CTLL-2 cells cultivated in the presence of
IL-2 were treated with 100 nM BraA for 0,
1, 2, and 4 hr.
(C) Amino acid deprivation inhibited the cell-
cycle progression at G1 phase. CTLL-2 cells
were cultivated for 18 hr in medium contain-
ing IL-2 but lacking His, Ile, Leu, Met, Phe,
Trp, Tyr, and Val.suggest that eIF2a phosphorylation induced by BraA
treatment is responsible for G1 arrest.
Immunosuppressive and Antitumor Activity of BraA
Previously, we reported that BraA exhibits immunosup-
pressive activity in a mouse mixed-lymphocyte reaction
assay [20, 21, 33, 34]; we have also reported cytotoxic
activity against several tumor cell lines in vitro [34, 35].
Both activated lymphocytes and tumor cells require
that metabolic substances be provided from the extra-
cellular environment for the support of their extraordi-
nary proliferation. To acquire amino acids, it has been
reported that tumor cells highly express the system L
component 4F2hc/LAT1 heterodimer [13, 15, 16]. There-
fore, inhibitors of nutrient transporters might provide
a novel class of immunosuppressants or antitumor
agents. In this context, BraA appears to be a good can-
didate agent. These results suggest that amino acidtransporters are novel targets for immunosuppressive
and antitumor therapies.
Significance
Both activated lymphocytes and tumor cells require
metabolic substances, such as sugars and amino
acids, for the support of their extraordinary prolifera-
tion. Since organic nutrients are provided to cells via
transporters situated on the plasma membrane, inhib-
itors of nutrient transporters might provide a novel
class of immunosuppressants or antitumor agents.
The result that a natural immunosuppressive and anti-
tumor product, BraA, targets the amino acid trans-
porter system L is in accord with this idea. Inhibition
of amino acid uptake by BraA decreases the amino
acid pool within the cells and causes the GCN2-depen-
dent integrated stress responses. Activation of
Brasilicardin A: a Potent System L Inhibitor
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retardation of cell proliferation. Because immunosup-
pression by tryptophan deprivation is suggested to be
a function of physiological immunoregulation, these
results suggest that amino acid transporters are novel
targets for immunosuppressant.
Experimental Procedures
Materials
BraA and its related compounds were purified as described previ-
ously [20, 33, 34]. Unless otherwise specified, all other materials
used were obtained from Sigma (Kent, UK). Jak inhibitor I [25] was
purchased from Merck Biosciences (Darmstadt, Germany). Anti-
ERK1, anti-phospho-ERK1/2 (Thr202/Tyr204), anti-Stat5, and anti-
phospho-Stat5 (Tyr694) antibodies were obtained from BD Bio-
sciences (Franklin Lakes, NJ). Anti-mTOR, anti-phospho-mTOR
(Ser2448), anti-p70 S6 kinase, anti-phospho-p70 S6 kinase
(Thr389), anti-phospho-p70 S6 kinase (Thr421/Ser424), anti-S6 ribo-
somal protein, anti-phospho-S6 ribosomal protein (Ser235/236),
anti-eIF2a, and anti-phospho-eIF2a (Ser51) antibodies were pur-
chased from Cell Signaling Technology, Inc. (Beverly, MA). Tritium-
labeled amino acids were obtained from GE Healthcare Bio-Science
Corporation (Piscataway, NJ). Recombinant human IL-2 was pre-
pared as described previously [36], with the expression plasmid
kindly provided by Dr. Fukushima at the Sasaki Institute.
Cell Culture and Flow Cytometry
A mouse T cell lymphoma cell line, CTLL-2, was obtained from
RIKEN Cell Bank (Ibaraki, Japan) and was maintained in RPMI
1640 medium supplemented with 10% fetal calf serum, 50 U/ml pen-
icillin, 50 mg/ml streptomycin, and 100 U/ml of rhIL-2 at 37C with 5%
CO2. HeLa cells were cultured in DMEM containing 10% fetal calf se-
rum, 50 U/ml penicillin, 50 mg/ml streptomycin, and 1 mM sodium py-
ruvate. Flow cytometry was performed as described previously [37].
Immunoblot Analysis
Cells were washed with phosphate-buffered saline (PBS) and lysed
in lysis buffer (50 mM Tris-HCl [pH7.4], 150 mM NaCl, 1 mM DTT,
1 mM EDTA, 50 mM NaF, 0.2 mM Na3VO4, and 1% Triton X-100), con-
taining protease inhibitors (Complete; Roche Applied Science, Indi-
anapolis, IN), by brief sonication on ice. The total soluble proteins
were obtained by centrifugation (20,000 3 g, 10 min, 4C), and the
proteins were separated by 10% SDS-PAGE. The proteins were
transferred to polyvinylidene difluoride membranes (Immobilon-P;
Millipore Corp., Billerica, MA), and were blocked with 5% nonfat
skim milk. All immunoblots used the aforementioned antibodies, di-
luted 1/1000 in Can Get Signal (Toyobo, Osaka, Japan). The protein
bands were visualized using the SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce, Rockford, IL).
Measurement of Amino Acid Uptake
The measurement of amino acid uptake was performed as previ-
ously described [38], with slight modifications. Briefly, HeLa cells
were seeded on 24-well plates (1 3 105 cells/well) in fresh growth
medium. After cultivation for 24 hr, the cells were washed three
times with standard uptake buffer (125 mM NaCl, 4.8 mM KCl, 1.3
mM CaCl2, 1.2 mM MgSO4, 25 mM HEPES, 1.2 mM KH2PO4, and
5.6 mM glucose [pH 7.4]), and were preincubated for 5 min in the
presence of drugs. The medium was then replaced by uptake solu-
tion containing tritium-labeled amino acids. Uptake was terminated
by removal of the uptake solution followed by washing the cells
three times with ice-cold uptake solution; cells were then solubilized
with 0.25 N NaOH. Radioactivity was measured by a liquid scintilla-
tion counter (LS6500 Multi-Purpose Scintillation Counter; Beckman
Coulter). For the measurement of the uptake of [3H]amino acids,
three wells of HeLa cells were used for each data point. To confirm
the reproducibility of the results, three or four separate experiments
were performed for each measurement.
To determine the Ki values, the uptake rate of [
3H]methionine were
measured for 5 min at 250, 333, 500, and 1000 mM, with or without
BraA. The Ki value was determined by double-reciprocal plot analy-sis in which 1/uptake rate of [3H]methionine was plotted against
1/methionine concentration.
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